Excitatory vs Inhibitory DREADD Circuit Switch: Controlling Neural Activity

What Are DREADDs?

DREADDs are designer receptors that can be activated by a synthetic ligand, clozapine N-oxide (CNO). These receptors are genetically engineered versions of natural G protein-coupled receptors. By expressing either the excitatory or inhibitory subtype in specific neurons, researchers can selectively control neuronal activity without affecting other cells.

The two main types of DREADDs used for this purpose are Gi and Gq. Gi-type DREADDs inhibit neurotransmitter release by activating an inhibitory G protein, while Gq-type DREADDs stimulate neurotransmitter release through a stimulatory G protein.

How Do DREADDs Work?

When CNO is administered to animals expressing DREADDs, it binds to the receptor and triggers a conformational change that activates the associated G protein. For Gi-type DREADDs, this leads to a decrease in intracellular cAMP levels and inhibition of adenylate cyclase, reducing neurotransmitter release. Conversely, for Gq-type DREADDs, CNO binding causes an increase in intracellular cAMP, activating adenylate cyclase and enhancing neurotransmitter release.

By selectively expressing these receptors in specific neuronal populations, scientists can modulate the activity of particular circuits or pathways with high precision, providing valuable insights into neural function and disease mechanisms.

Why Does This Matter?

The ability to control neural circuitry using DREADDs has revolutionized our understanding of brain function. It allows researchers to dissect complex behaviors and neurological disorders at the cellular level, offering potential therapeutic strategies for conditions like depression, anxiety, and Parkinson's disease.

Moreover, DREADD technology can be used in preclinical studies to test novel treatments or drug candidates before human trials, accelerating the development of new therapies.

Real-World Applications

In clinical settings, DREADDs have been proposed as a means to modulate neural activity in specific brain regions. For instance, in Parkinson's disease, Gq-type DREADDs could be used to enhance the release of dopamine, potentially alleviating motor symptoms.

Additionally, researchers are exploring the use of DREADDs for treating psychiatric disorders by selectively inhibiting or exciting neuronal populations associated with mood regulation.

Frequently asked questions

Try it live

Everything above runs in your browser — open Excitatory vs Inhibitory DREADD Circuit Switch and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.